CJC-1295 (No DAC) / Hexarelin Blend is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: CJC-1295 without Drug Affinity Complex (No DAC) and Hexarelin. CJC-1295 (No DAC) is a modified growth hormone–releasing hormone (GHRH) analog, while Hexarelin is a potent growth hormone secretagogue receptor (GHS-R) agonist derived from the growth hormone–releasing peptide family. Together, this blend is formulated for laboratory research focused on growth hormone release dynamics, receptor activation pathways, and endocrine signaling mechanisms.
Prior to the targeted synthesis and characterization of these peptides, research into growth hormone stimulation relied largely on less selective secretagogues and broader hormonal approaches. In controlled research settings, CJC-1295 (No DAC) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a shorter duration of action compared to DAC-bound variants. Hexarelin has been extensively researched for its strong receptor affinity and its role in stimulating growth hormone secretion via ghrelin receptor pathways. The combination allows researchers to examine complementary mechanisms involved in growth hormone pulsatility, secretion amplitude, and coordinated pituitary signaling models.
Currently, the CJC-1295 (No DAC) / Hexarelin Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional research continues to explore its role in downstream anabolic signaling, cardiovascular-related research pathways, and circadian growth hormone release patterns. Due to the complementary research interest of these peptides, this blend remains a valuable subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The CJC-1295 (No DAC), Hexarelin Blend is formulated for laboratory research examining growth hormone signaling pathways, endocrine communication mechanisms, and pulsatile hormone response patterns. By combining a growth hormone–releasing hormone (GHRH) analog with a potent growth hormone secretagogue, this peptide blend allows researchers to investigate how upstream hypothalamic signaling interacts with ghrelin receptor–mediated pituitary responses.
In experimental models focused on the GH-axis, multi-peptide protocols are often used to explore signaling amplification, pulse frequency changes, and downstream endocrine marker responses across defined sampling intervals. Because blend research introduces additional variables, well-designed studies emphasize strict endpoint definitions, consistent environmental conditions, and careful documentation of experimental variables to maintain reproducibility.
CJC-1295 (No DAC), Hexarelin Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | CJC-1295 (No DAC) + Hexarelin |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
CJC-1295 without DAC is commonly studied in peptide research as a modified GHRH analog used to explore pulsatile growth hormone signaling patterns. Because this version lacks the Drug Affinity Complex (DAC) modification found in certain long-acting variants, it is often evaluated in experimental models where researchers want to observe shorter hormone signaling windows and more defined pulse-response relationships.
Hexarelin is a growth hormone secretagogue widely referenced in research literature for its interaction with ghrelin receptors and its role in GH-axis signaling experiments. Laboratory studies frequently investigate hexarelin within endocrine pathway models, examining pituitary response behavior and associated biomarker changes under controlled conditions.
When these peptides are combined within a research protocol, investigators can evaluate how GHRH stimulation and ghrelin receptor activation influence growth hormone signaling dynamics together. Comparative research designs may analyze pulse amplitude, hormone release patterns, or downstream metabolic marker fluctuations to better understand combined pathway behavior.
Researchers studying the compounds independently can reference the individual product pages for CJC-1295 (without DAC) and Hexarelin.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
One common research application of this blend involves analyzing pulsatile growth hormone signaling patterns. Investigators may measure endocrine markers across timed sampling intervals to observe how dual pathway stimulation affects GH release amplitude and frequency.
Because both peptides influence components of the GH-axis, this blend is frequently examined in endocrine pathway research evaluating pituitary responsiveness and hormonal communication dynamics in laboratory models.
In many peptide research programs, blended protocols are compared against individual peptide conditions. This design structure allows researchers to determine whether combined pathway activation produces additive, synergistic, or independent signaling outcomes.
Growth hormone pathway studies often overlap with metabolic marker analysis and cellular signaling research. Controlled experimental systems may track variables such as endocrine biomarkers, metabolic indicators, and recovery-related markers influenced by GH-axis activity.
The CJC-1295 (No DAC), Hexarelin Blend should be handled using standard peptide laboratory procedures, including proper storage practices, contamination control, and detailed experimental documentation. Consistent laboratory conditions help ensure reliable and reproducible research outcomes.
Protocol Design Considerations: Growth hormone signaling experiments are sensitive to circadian timing, baseline metabolic status, stress exposure, and environmental variables. Carefully controlled laboratory conditions and standardized sampling windows improve experimental reliability.
Note: The information above is provided as a research reference summary only. All experimental work must be conducted by qualified personnel in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis verifying identity and quality parameters. These analytical documents assist research teams with procurement verification, regulatory documentation, and reproducibility tracking across study phases.
When sourcing peptides for endocrine signaling research, laboratories typically prioritize traceable documentation, reliable synthesis standards, and strict quality-control processes. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and consistent manufacturing standards designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
